JAAOS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zimlich, R.
Right arrow Articles by Friedman, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zimlich, R.
Right arrow Articles by Friedman, R.

Current Status of Anticoagulation Therapy After Total Hip and Total Knee Arthroplasty

RH Zimlich, BM Fulbright and RJ Friedman

Department of Orthopaedic Surgery, Medical University of South Carolina, Charleston.

Postoperative venous thromboembolism in the pelvis and lower extremities is a potentially life-threatening complication in patients undergoing elective total hip and total knee arthroplasty. Numerous pharmacologic methods of prophylaxis have been used in the past with varying degrees of success. Warfarin has been proved effective as a prophylactic agent after total hip arthroplasty but has been less efficacious after total knee arthroplasty. The low-molecular-weight heparins have recently been approved for prophylaxis after total hip and total knee arthro-plasty and are an acceptable alternative to warfarin. This new class of drugs appears to have the advantage of predictable subcutaneous bioavailability, which allows less frequent administration and laboratory monitoring and offers a decrease in the occurrence of side effects.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Academy of Orthopaedic Surgeons.